Review of JPM 2026 – Nvidia & Lilly Deal

Nvidia–Lilly: a $1B reminder that compute is becoming a strategic supply chain

The most emblematic AI announcement at JPM wasn’t a new foundation model paper. It was infrastructure: Eli Lilly and Nvidia committing $1B over five years for a joint research lab in the Bay Area.

Why it matters (beyond the headline):

• Pharma is treating compute as a strategic resource, not a line item.
• The competitive edge shifts toward teams who can pair compute with proprietary data, tightly scoped use cases, and deployment discipline.
• It hints at an ecosystem where hardware, cloud, and model tooling are bundled into “drug discovery stacks.”

Charlotte’s POV: “If compute and foundational tooling get commoditised, your differentiation must move up the stack: data readiness, experimental feedback loops, domain constraints, and workflow integration.”